Blue Heron Biotechnology Obtains Exclusive Worldwide License To Gene Synthesis Patent
Blue Heron Biotechnology today announced that it has obtained an exclusive worldwide license to a gene synthesis patent issued to Amgen Inc. (Nasdaq: AMGN - news). The United States Patent and Trademark Office issued patent 4,652,639 to Amgen in 1987. Subsequently the patent was issued in Canada, Japan, Israel, and most of Western Europe. The patent describes rapid and highly efficient procedures for the synthesis of linear, double stranded DNA. Under the terms of the agreement, Blue Heron Biotechnology is the sole licensee and has the right to sublicense while Amgen retains certain rights to practice under the patent.
``We are committed to building our intellectual property position through patent filings and licensing agreements that protect and expand our leadership position in the emerging market for gene synthesis,'' said Peter Nicholson, President & Chief Executive Officer. ``This patent may be a significant obstacle to others seeking to enter this market.''
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Synthesis
Chemical synthesis is at the heart of modern chemistry and enables the targeted production of molecules with specific properties. By combining starting materials in defined reaction conditions, chemists can create a wide range of compounds, from simple molecules to complex active ingredients.
Topic world Synthesis
Chemical synthesis is at the heart of modern chemistry and enables the targeted production of molecules with specific properties. By combining starting materials in defined reaction conditions, chemists can create a wide range of compounds, from simple molecules to complex active ingredients.